BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1037 related articles for article (PubMed ID: 32108359)

  • 21. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2.
    Kalita P; Padhi AK; Zhang KYJ; Tripathi T
    Microb Pathog; 2020 Aug; 145():104236. PubMed ID: 32376359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain:
    Chukwudozie OS; Chukwuanukwu RC; Iroanya OO; Eze DM; Duru VC; Dele-Alimi TO; Kehinde BD; Bankole TT; Obi PC; Okinedo EU
    J Immunol Res; 2020; 2020():2837670. PubMed ID: 32964056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of SARS-CoV-2 vaccine candidates.
    Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
    Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach.
    Abdelmageed MI; Abdelmoneim AH; Mustafa MI; Elfadol NM; Murshed NS; Shantier SW; Makhawi AM
    Biomed Res Int; 2020; 2020():2683286. PubMed ID: 32461973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome.
    Crooke SN; Ovsyannikova IG; Kennedy RB; Poland GA
    Sci Rep; 2020 Aug; 10(1):14179. PubMed ID: 32843695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.
    Panda PK; Arul MN; Patel P; Verma SK; Luo W; Rubahn HG; Mishra YK; Suar M; Ahuja R
    Sci Adv; 2020 Jul; 6(28):eabb8097. PubMed ID: 32691011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conserved HLA binding peptides from five non-structural proteins of SARS-CoV-2-An in silico glance.
    Marchan J
    Hum Immunol; 2020; 81(10-11):588-595. PubMed ID: 32888767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.
    Khalaj-Hedayati A
    J Immunol Res; 2020; 2020():7201752. PubMed ID: 32695833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the SARS-CoV-2 structural proteins for multi-epitope vaccine development: an
    Kumar A; Kumar P; Saumya KU; Kapuganti SK; Bhardwaj T; Giri R
    Expert Rev Vaccines; 2020 Sep; 19(9):887-898. PubMed ID: 32815406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein: A computational approximation.
    Marchan J
    J Immunol Methods; 2022 Mar; 502():113216. PubMed ID: 35007561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2.
    Kiyotani K; Toyoshima Y; Nemoto K; Nakamura Y
    J Hum Genet; 2020 Jul; 65(7):569-575. PubMed ID: 32372051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics.
    Jakhar R; Kaushik S; Gakhar SK
    J Med Virol; 2020 Oct; 92(10):2114-2123. PubMed ID: 32379348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country.
    Requena D; Médico A; Chacón RD; Ramírez M; Marín-Sánchez O
    Front Immunol; 2020; 11():2008. PubMed ID: 33013857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Landscape and selection of vaccine epitopes in SARS-CoV-2.
    Smith CC; Olsen KS; Gentry KM; Sambade M; Beck W; Garness J; Entwistle S; Willis C; Vensko S; Woods A; Fini M; Carpenter B; Routh E; Kodysh J; O'Donnell T; Haber C; Heiss K; Stadler V; Garrison E; Sandor AM; Ting JPY; Weiss J; Krajewski K; Grant OC; Woods RJ; Heise M; Vincent BG; Rubinsteyn A
    Genome Med; 2021 Jun; 13(1):101. PubMed ID: 34127050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research.
    Chen Z; Ruan P; Wang L; Nie X; Ma X; Tan Y
    J Cell Mol Med; 2021 Jan; 25(2):1274-1289. PubMed ID: 33325143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ancestral origin, antigenic resemblance and epidemiological insights of novel coronavirus (SARS-CoV-2): Global burden and Bangladesh perspective.
    Uddin MB; Hasan M; Harun-Al-Rashid A; Ahsan MI; Imran MAS; Ahmed SSU
    Infect Genet Evol; 2020 Oct; 84():104440. PubMed ID: 32622082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19.
    Xu W; Wang M; Yu D; Zhang X
    Front Immunol; 2020; 11():565278. PubMed ID: 33013929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19.
    Ojha R; Gupta N; Naik B; Singh S; Verma VK; Prusty D; Prajapati VK
    Eur J Pharm Sci; 2020 Aug; 151():105375. PubMed ID: 32417398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of novel multiepitope constructs-based peptide vaccine against the structural S, N and M proteins of human COVID-19 using immunoinformatics analysis.
    Khairkhah N; Aghasadeghi MR; Namvar A; Bolhassani A
    PLoS One; 2020; 15(10):e0240577. PubMed ID: 33057358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epitopes for a 2019-nCoV vaccine.
    Lucchese G
    Cell Mol Immunol; 2020 May; 17(5):539-540. PubMed ID: 32094505
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.